Back to Search
Start Over
Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis.
- Source :
- NPJ Vaccines; 6/18/2021, Vol. 6 Issue 1, p1-9, 9p
- Publication Year :
- 2021
-
Abstract
- Activation of antigen-specific T-lymphocyte responses may be needed to cure disorders caused by chronic infection with low-risk human papillomavirus (lrHPV). Safe and effective adjuvant therapies for such disorders are needed. The safety and efficacy of a novel gorilla adenovirus vaccine expressing a protein designed to elicit immune responses directed against HPV6 and HPV11, PRGN-2012, was studied using in vitro stimulation of T lymphocytes from patients with recurrent respiratory papillomatosis, in vivo vaccination studies, and therapeutic studies in mice bearing tumors expressing lrHPV antigen. PRGN-2012 treatment induces lrHPV antigen-specific responses in patient T lymphocytes. Vaccination of wild-type mice induces E6-specific T-lymphocyte responses without toxicity. In vivo therapeutic vaccination of mice bearing established HPV6 E6 expressing tumors results in HPV6 E6-specific CD8+ T-lymphocyte immunity of sufficient magnitude to induce tumor growth delay. The clinical study of PRGN-2012 in patients with disorders caused by chronic infection with lrHPV is warranted. [ABSTRACT FROM AUTHOR]
- Subjects :
- T cells
HUMAN papillomavirus vaccines
ADENOVIRUSES
IMMUNE response
TUMOR growth
Subjects
Details
- Language :
- English
- ISSN :
- 20590105
- Volume :
- 6
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- NPJ Vaccines
- Publication Type :
- Academic Journal
- Accession number :
- 150974251
- Full Text :
- https://doi.org/10.1038/s41541-021-00348-x